作者: Michael R. Verneris , Claudio G. Brunstein , Juliet Barker , Margaret L. MacMillan , Todd DeFor
DOI: 10.1182/BLOOD-2009-05-220525
关键词:
摘要: Umbilical cord blood (UCB) transplantation is potentially curative for acute leukemia. This analysis was performed to identify risk factors associated with leukemia relapse following myeloablative UCB transplantation. Acute patients (n = 177; 88 lymphoblastic and 89 myeloid leukemia) were treated at a single center. Patients received graft composed of either 1 (47%) or 2 (53%) partially human leukocyte antigen (HLA)-matched unit(s). Conditioning cyclophosphamide total body irradiation without fludarabine. The incidence 26% (95% confidence interval [CI], 19%-33%). In multivariate analysis, higher in advanced disease (> third complete remission [CR3]; relative [RR], 3.6; P < .01), trend toward less recipients units (RR 0.6; .07). However, lower CR1-2 who 0.5; .03). Leukemia-free survival 40% CI, 30%-51%) 51% 41%-62%) single- double-unit recipients, respectively (P .35). Although it known that CR1 CR2 risk, this reveals an enhanced graft-versus-leukemia effect after HLA-matched units. trial registered http://clinicaltrials.gov as NCT00309842.